89 reports

  • GLOBAL ANTITHROMBOTIC DRUGS MARKET IN 2022 - GROWTH STRATEGIES

IN RUSSIA ##. ##% OF DEATHS OCCUR FROM CORONARY HEART DISEASE (CHD) AND ##. ##% FROM CEREBROVASCULAR DISEASE, MOSTLY STROKES.

  • Blood Disease
  • Cardiovascular Disease
  • World
  • Forecast
  • Johnson & Johnson

Interventional cardiology offers products for treating conditions such as, cardiovascular disease, coronary artery disease and acute myocardial infarction.

  • Blood Disease
  • World
  • Forecast
  • Market Size
  • Medtronic, Inc.

FURTHERMORE, XARELTO IS LISTED AS BEING IN PHASE III DEVELOPMENT FOR THE FOLLOWING: CHRONIC HEART FAILURE AND CORONARY ARTERY DISEASE; LONG-TERM VTE PREVENTION IN HIGH-RISK, MEDICALLY ILL PATIENTS; AND THE PREVENTION OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH

  • Blood Disease
  • Boehringer Ingelheim GmbH
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • RECOMBINANT PROTEIN FOR CORONARY ARTERY DISEASE - DRUG PROFILE
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY CSL LTD, H2 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview Coronary artery disease (CAD) is the most common type of heart disease.

  • Blood Disease
  • Cardiovascular Disease
  • Cell Therapy
  • United States
  • Product Initiative
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY VERSEON CORP, H1 2019
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY VESSL THERAPEUTICS LTD, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview Coronary artery disease (CAD) is the most common type of heart disease.

  • Blood Disease
  • Cardiovascular Disease
  • United States
  • Company
  • Product Initiative
  • 2.2 PULMONARY EMBOLISM: AN OVERVIEW

This approved new drug application provides for the use of RUBY-FILL for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary

  • Blood Disease
  • World
  • Market Size
  • Cyclopharm Limited
  • Lifesciences Limited

George' s University of London, where she characterized a novel subtype of CD##+ T lymphocytes in coronary artery disease, which is a potential therapeutic target.

  • Blood Disease
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Novartis AG
  • Promedior, Inc.
  • RIVAROXABAN - DRUG PROFILE
  • VE-1902 - DRUG PROFILE

The study will include ##, ## patients in ## countries, COMPASS will evaluate Xarelto in patients with coronary artery disease or peripheral artery disease.

  • Blood Disease
  • China
  • United States
  • World
  • Product Initiative
  • RIVAROXABAN - DRUG PROFILE
  • VE-1902 - DRUG PROFILE

The study will include ##, ## patients in ## countries, COMPASS will evaluate Xarelto in patients with coronary artery disease or peripheral artery disease.

  • Blood Disease
  • Chronic Disease
  • United States
  • World
  • Product Initiative
  • VE-1902 - Drug Profile
  • such as the arteriovenous shunt and thrombin-induced thromboembolism models, the VE-DTIs leave platelet function unaffected.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot.

  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • VE-1902 - Drug Profile
  • such as the arteriovenous shunt and thrombin-induced thromboembolism models, the VE-DTIs leave platelet function unaffected.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot.

  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • PZ-128 - DRUG PROFILE
  • S-007867 - DRUG PROFILE

GLS-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description GLS-## GLSYNTHESIS INC NA NA GLS-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF CORONARY ARTERY THROMBOSIS.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • XBiotech Inc.
  • Clinical Trial profile. 283 Trial Title

Rosuvastatin on Platelet Reactivity in Stable Patients with Coronary Artery Disease Treated with Dual Antiplatelet Therapy Pharmacodynamic Effects of Atorvastatin vs.

  • Blood Disease
  • Clinical Trial
  • Therapy
  • World
  • AstraZeneca PLC
  • TICAGRELOR - DRUG PROFILE

The overall THEMIS trial population was patients with coronary artery disease (CAD) and type ## diabetes (T##D) with no prior heart attack or stroke.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • TICAGRELOR - DRUG PROFILE
  • TICAGRELOR - DRUG PROFILE

The overall THEMIS trial population was patients with coronary artery disease (CAD) and type ## diabetes (T##D) with no prior heart attack or stroke.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

ASA Only After Isolated Coronary Artery Bypass Grafting in Patient with Acute Coronary Syndrome Ticagrelor and ASA vs.

  • Angina
  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • World

" Olivia will have lifelong issues related to her heart and coronary arteries, " said Portman.

  • Blood Disease
  • Cancer
  • Clinical Trial
  • United States
  • Company
  • 5. All the trials included are unique trials.

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH- HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ##; CTRI/ 2017/ ##/ ##; SKNMC/ Ethics/ Corr/ 2016/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease,

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Therapy
  • Bayer AG
  • PZ-128 - DRUG PROFILE
  • S-007867 - DRUG PROFILE

GLS-## - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description GLSYNTHESIS INC GLS-## NA NA GLS-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF CORONARY ARTERY THROMBOSIS.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH- HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ##; CTRI/ 2017/ ##/ ##; SKNMC/ Ethics/ Corr/ 2016/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease,

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Compression Therapy
  • Bayer AG
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Therapy
  • Bayer AG

The present disclosure relates to HIF-## alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-## alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary

  • Blood Disease
  • China
  • United States
  • Company
  • Product Initiative

The present disclosure relates to HIF-## alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-## alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary

  • Blood Disease
  • China
  • East Asia
  • Japan
  • United States
  • Official Title
  • Clinical Trial profile. 480 Trial Title

(Woest ##) GDCT## NCT##, R& D/ Z##. ##/ WOEST##; WOEST##-##; V. ##/ W##. ## Cardiovascular Acute Coronary Syndrome, Atrial Fibrillation, Bleeding And Clotting Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Heart

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • RIVAROXABAN - DRUG PROFILE
  • RIVAROXABAN - DRUG PROFILE

PAD costs exceed diabetes, coronary artery disease and cancers.

  • Blood Disease
  • Cardiovascular Disease
  • Therapy
  • United States
  • Product Initiative

Reddy' s Laboratories Ltd., India and Plavix (Clopidogrel Bisulfate) ## mg Tablets Under Fasting Conditions Bioequivalence Study of Clopidogrel Tablets ## mg under Fasting Conditions GDCT## NCT##, ##-## Hematological Disorders Acute Coronary Syndrome, Angina (Angina Pector

  • Blood Disease
  • Drug Development
  • Pharmaceutical
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • Clinical Trial Profile Snapshots

KG) and Plavix ##mg Film Coated Tablets in Healthy Volunteers under Fasted Conditions GDCT## GDC##, Cardiovascular Acute Coronary Syndrome, Acute Ischemic Stroke, Arterial Thrombosis, Myocardial Infarction, Peripheral Arterial Disease (PAD)/ Peripheral Vascular

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • World
  • Product Initiative
  • Clinical Trial profile. 1380 Trial Title
  • Official Title

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH-HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Deep Vei

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Pharmaceutical
  • World

The risk factors for stroke are similar to those for coronary heart disease and other vascular diseases.

  • Blood Disease
  • United States
  • Company
  • Market Segment
  • Laboratorios Farmacéuticos Rovi, S.A.